With co-founders from Stanford University and National University of Singapore, Nuevocor aims to develop gene therapies for cardiomyopathies.
Nuevocor, a Singapore-based developer of gene therapies for cardiomyopathies co-founded by Stanford University and National University of Singapore researchers, secured $24m in a series A round yesterday.
Pharmaceutical firm and Boehringer Ingelheim co-led the round through subsidiary Boehringer Ingelheim Venture Fund together with EVX Ventures. The round also included Xora Innovation and the state-owned EDBI and Seeds Capital as well as undisclosed other investors.
Nuevocor is working on an adeno-associated virus-based gene therapy for patients suffering from a…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
